Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study
The Oncologist · 29.06.2026
DOI: 10.1093/oncolo/oyag247 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 29.06.2026. Verfasst von Bohan Li und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Hematopoietic stem cell transplantation (HSCT) is a curable treatment for refractory/relapse B-cell acute lymphoblastic leukemia (R/R B-ALL).Traditional chemotherapy or Chimeric antigen receptor T-cell (CAR-T) therapy are both important methods to achieve MRD negativity before HSCT. However, which treatment is preferred needs to be clarified. Patients and Methods In this study, 269 patient s with R/R B-ALL who underwent allo-HSCT after CAR-T cell therapy (CAR-T, n = 142) or chemotherapy (CT, n = 127) were enrolled from multicenters.
Results
The 3-year overall survival (OS) after transplantation was 66.8% in the CAR-T group and 72.3% in the chemotherapy (CT) group. The 3-year relapse-free survival (RFS) was 65.3% in the CAR-T group and 65.9% in the CT group. The 3-year graft-versus-host disease, relapse-free survival (GRFS) and cumulative incidence of relapse (CIR) were also similar between the two groups. Among patients who achieved first complete remission (CR1) before transplantation, the proportion receiving chemotherapy was significantly higher than that receiving CAR-T therapy (37.5% vs. 13.6%; P < 0.001). In this CR1 subgroup, the CT group demonstrated superior outcomes, including improved OS, RFS, and GRFS.
Conclusion
In pediatric R/R B-ALL, CAR-T bridging to HSCT appears to yield post-transplant survival comparable to chemotherapy, though a higher rate of moderate to severe chronic GVHD was observed. CAR-T may be a reasonable option, but closer GVHD monitoring seems warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, China.
- Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, China.
- Department of Pediatrics, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.
- Department of Pediatrics, Hong Kong Children's Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
- State Key Laboratory of Experimental Hematology and Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Ti…
- Department of Hematology/Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China.
Zitieren
APA
Li, B., Luo, C., Lu, J., Cai, J., Zhu, Y., Li, C. K., Guo, Y., Jiang, H., Huang, X., Cheng, Y., Pan, J., Sun, Z., Feng, X., Liu, X., Chen, K., Yu, J., He, G., Wang, J., Liu, A., …, & Hu, S. (2026). Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study. The Oncologist. https://doi.org/10.1093/oncolo/oyag247
Vancouver
Li B, Luo C, Lu J, Cai J, Zhu Y, Li CK, et al. Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study. The Oncologist. 2026. doi:10.1093/oncolo/oyag247
BibTeX
@article{Li2026,
author = {Li, Bohan and Luo, Chengjuan and Lu, Jun and Cai, Jiaoyang and Zhu, Yiping and Li, Chi-Kong and Guo, Ye and Jiang, Hua and Huang, Xiaohang and Cheng, Yifei and Pan, Jing and Sun, Zimin and Feng, Xiaoqin and Liu, Xuan and Chen, Kai and Yu, Jie and He, Guangcui and Wang, Jingbo and Liu, Aiguo and Wu, Xiaoyan and Wan, Liping and Wang, Hongmei and Xiao, Xia and Qin, Maoquan and Pan, KaiLi and Lu, Jing and Xiao, Peifang and Chen, Jing and Sun, Ruijuan and Hu, Shaoyan},
title = {Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag247}
}
EUVIMED